Research programme: inhaled chemotherapies - InhaTarget Therapeutics
Latest Information Update: 06 Nov 2024
Price :
$50 *
At a glance
- Originator InhaTarget Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 05 Nov 2024 Preclinical trials in Lung cancer in Belgium (Inhalation), before November 2024 (InhaTarget Therapeutics pipeline, November 2024)